ArticleJournal of oral biology and craniofacial research
Sulfiredoxin levels in gingival crevicular fluid: A new antioxidant defence system- case control study.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Periodontitis is a chronic inflammatory condition in which oxidative stress plays a major role in its pathogenesis. The redox balance in the body acts as a defense system to counter this stress. The Peroxiredoxin (Prx)- Sulfiredoxin (Srx) antioxidant system is one such mechanism, found to be active in many systemic inflammatory diseases, including periodontitis. This study aims to compare the levels of Srx in Gingival Crevicular Fluid (GCF) of healthy and periodontally compromised patients after Non-surgical Periodontal Therapy (NSPT). Methods: A total of 40 participants were divided into two groups: Group I included systemically and periodontally healthy individuals (control group), while Group II included patients diagnosed with chronic periodontitis (case group). Both groups received NSPT and were reassessed after three months. Clinical parameters such as Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD), and Clinical Attachment Loss (CAL) were recorded and GCF samples were collected to measure Srx levels using the Enzyme-Linked Immunosorbent Assay (ELISA) at baseline and after three months. Results: Srx levels significantly reduced after therapy in both groups. In Group I, levels decreased from 0.505 ± 0.20 ng/ml to 0.301 ± 0.13 ng/ml (p = 0.005). In Group II, levels decreased from 0.532 ± 0.23 ng/ml to 0.366 ± 0.10 ng/ml (p = 0.004). All clinical parameters also showed significant improvement at three months. Conclusion: Srx levels decreased significantly after NSPT, suggesting its role as a potential biochemical marker to evaluate treatment outcomes. Further studies with larger samples and longer follow-ups are needed to confirm its diagnostic and prognostic value in periodontal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.